Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in non-small cell lung cancer
NCT00076388Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung carcinoma (NSCLC), sponsored by AstraZeneca. Started Feb 2004; status: completed.
02
Drugs
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00076388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076388.